Patents Assigned to Calimmune Inc.
  • Modulatable switch for selection of donor modified cells
    Patent number: 10426798
    Abstract: The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 1, 2019
    Assignees: Calimmune, Inc., Calimmune Australia PTY LTD
    Inventors: Christopher Walter Alma, Jeffrey Bartlett, Louis Randall Breton, Geoffrey Phillip Symonds, Ming Yan
  • Methods for discriminating between HIV-1 and lentiviral vectors
    Patent number: 10240214
    Abstract: The present disclosure provides compositions (i.e., amplification primers and probes), methods, and kits that are particularly useful for detecting and/or quantifying nucleic acids present in a sample, such as those derived from HIV or a lentiviral vector.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 26, 2019
    Assignees: Calimmune, Inc., Calimmune Australia Pty Ltd, St. Vincent's Hospital Sydney Limited, Newsouth Innovations Pty Limited
    Inventors: Anthony Dominic Kelleher, Kazuo Suzuki, Geoffrey Phillip Symonds
  • Bio-production of lentiviral vectors
    Patent number: 10138495
    Abstract: The present disclosure provides a method of generating a stable producer cell line. The generation of stable producer cell lines, such as those provided in accordance with the present invention, increases the reproducibility and ease of creating high titer lentiviral stocks while easing biosafety concerns and the variation in expressed envelope proteins defines the tropism of the generated virus. The present disclosure also provides for a novel lentiviral transfer vector plasmid.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: November 27, 2018
    Assignee: Calimmune, Inc.
    Inventors: Chi-Lin Lee, Jeffrey S Bartlett
  • DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS
    Publication number: 20120201794
    Abstract: The present invention provides an expression vector for preventing or inhibiting HIV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HIV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and/or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed.
    Type: Application
    Filed: May 26, 2010
    Publication date: August 9, 2012
    Applicant: Calimmune Inc.
    Inventors: Irvin Chen, Dong Sung An, Michelle L. Millington, Maureen P. Boyd, Geoffrey P. Symonds, Louis Randall Breton